Hypnotic and Sedative Drug Use: Dosing, Duration, and Contraindications
For short-term insomnia treatment in adults without significant comorbidities, use zolpidem 10 mg, eszopiclone 2-3 mg, or temazepam 15 mg at bedtime, limiting treatment to 4 weeks or less to minimize risks of dependence, cognitive impairment, and serious adverse events including fractures and dementia. 1
Recommended Agents and Dosing
The 2017 American Academy of Sleep Medicine (AASM) guidelines provide the most comprehensive, evidence-based framework for pharmacologic treatment:
For Sleep Onset Insomnia:
- Zolpidem 10 mg at bedtime (reduces sleep latency by mean 29 minutes vs placebo) 1
- Eszopiclone 2-3 mg at bedtime (effective for both onset and maintenance) 1
- Temazepam 15 mg at bedtime (improves total sleep time by 99 minutes vs placebo) 1
- Triazolam 0.25 mg at bedtime (alternative benzodiazepine option) 1
For Sleep Maintenance Insomnia:
- Eszopiclone 2-3 mg (reduces wake after sleep onset by 10-14 minutes) 1
- Zolpidem 10 mg (reduces wake after sleep onset by 25 minutes) 1
- Temazepam 15 mg (particularly effective for maintenance) 1
- Doxepin 3-6 mg (reduces wake after sleep onset by 22-23 minutes) 1
Lorazepam Dosing:
While not specifically recommended in the AASM guidelines, the FDA label indicates: 2-4 mg as a single daily dose at bedtime for insomnia due to anxiety or transient situational stress 2. Start with 2 mg in most adults; elderly or debilitated patients should start at 1-2 mg daily 2.
Duration of Treatment
Maximum recommended duration: 4 weeks 3. This is critical because:
- Most efficacy trials were short-term (4 weeks or less) 3
- Risk of dependence increases with prolonged use 2
- Observational studies link chronic hypnotic use to increased dementia, fractures, and major injury 3
- Tolerance may develop with extended use, though this varies by agent 4
Discontinuation strategy: After short-term use (1-2 weeks), abrupt discontinuation is acceptable for non-benzodiazepine agents 5. For use beyond 2 weeks, taper gradually with 10-25% weekly dose reductions to avoid withdrawal symptoms 2, 5.
Critical Contraindications and Precautions
Absolute Contraindications:
- Known hypersensitivity to the specific agent
- Severe hepatic impairment (relative; requires dose reduction to 2 mg for eszopiclone) 6
Relative Contraindications and Dose Adjustments:
Elderly patients (≥65 years):
- Eszopiclone: Maximum 2 mg (41% increase in drug exposure, prolonged half-life to ~9 hours) 6
- Zolpidem: Consider 5 mg (FDA recommends lower doses due to next-day impairment risk) 3
- Lorazepam: Start 1-2 mg 2
- Temazepam: 15 mg acceptable but monitor closely 1
Hepatic impairment:
- Severe impairment: Eszopiclone maximum 2 mg (2-fold increase in exposure) 6
- Lorazepam requires dose adjustment 2
Renal impairment:
- No dose adjustment needed for eszopiclone 6
High-Risk Situations Requiring Caution:
Avoid or use extreme caution with:
- Concurrent CNS depressants (alcohol, opioids, other sedatives) - additive effects increase respiratory depression risk 6
- History of substance abuse - higher dependence potential 3
- Driving or operating machinery within 7-8 hours of dosing - impaired next-day performance, especially with 2-3 mg eszopiclone 6
- Women may have higher morning blood levels and increased next-day impairment risk 6
Administration Guidelines
Timing and food interactions:
- Take immediately before bedtime with at least 7-8 hours available for sleep 6
- Do NOT take with or after heavy, high-fat meals - delays absorption by ~1 hour and reduces efficacy for sleep onset 6
- Eszopiclone absorption is reduced 21% in Cmax with high-fat meals 6
Lorazepam oral concentrate:
- Must be mixed with liquid or semi-solid food (water, juice, applesauce)
- Use only calibrated dropper provided
- Consume entire mixture immediately; do not store 2
Common Adverse Effects Profile
Based on network meta-analysis and FDA data 3, 7:
Most common nervous system effects:
- Somnolence: Zolpidem (RR 1.85), Eszopiclone (RR 2.00), Temazepam (RR 3.77), Lorazepam (common)
- Dizziness: Zolpidem (RR 2.33), Eszopiclone (RR 3.18)
- Headache: Zolpidem (RR 1.26)
- Dysgeusia (bad taste): Eszopiclone (RR 10.54) - very common and distinctive
Gastrointestinal effects:
- Dry mouth: Zolpidem (RR 1.92), Eszopiclone (RR 4.39)
- Nausea (less common)
Serious but rare adverse events:
- Complex sleep behaviors (sleep-driving, sleep-eating) - FDA black box warning for all agents
- Cognitive and behavioral changes
- Anterograde amnesia
- Falls and fractures (especially elderly)
- Paradoxical anxiety (zolpidem RR 3.32) 7
Critical Safety Warnings
FDA-mandated warnings apply to all agents:
- Risk of next-day driving impairment, particularly with higher doses 3, 6
- Potential for cognitive and behavioral changes 3
- Dose reduction advised for women and elderly 3
Long-term observational data suggests associations with:
- Increased dementia risk
- Increased fracture risk
- Major injury 3
These associations emphasize the importance of limiting duration to short-term use only.
Agents NOT Recommended
The AASM explicitly recommends against using 1:
- Diphenhydramine (no improvement in sleep quality)
- Trazodone 50 mg
- Melatonin 2 mg
- Valerian
- L-tryptophan
Practical Algorithm for Selection
Identify insomnia type:
- Sleep onset only → Zolpidem 10 mg, Eszopiclone 2-3 mg, or Triazolam 0.25 mg
- Sleep maintenance only → Eszopiclone 2-3 mg, Temazepam 15 mg, or Doxepin 3-6 mg
- Both onset and maintenance → Eszopiclone 2-3 mg, Zolpidem 10 mg, or Temazepam 15 mg
Adjust for patient factors:
- Age ≥65 → Reduce doses (eszopiclone max 2 mg, consider zolpidem 5 mg)
- Severe hepatic impairment → Eszopiclone max 2 mg
- Concern about taste → Avoid eszopiclone (dysgeusia very common)
Set treatment duration: Maximum 4 weeks
Plan discontinuation: Taper if used >2 weeks (10-25% weekly reduction)
Combine with cognitive-behavioral therapy for insomnia (CBT-I) when possible for optimal outcomes 5